Valsartan

Valsartan has been studied in 24 papers since 2009: 3 trials and 5 observational studies in people, 8 in animals, 4 in cells, 2 reviews; 9 in the past year. It is an approved medicine. The newest paper, Oct 26, 2026: “Risk of incident gout and major adverse cardiovascular events according to angiotensin receptor blocker type in amlodipine-based combination therapy:…”.

InterventionApproved 1996

24 papers study it23 more mention it19 findingsUpdated

PubChemChEBIMeSH

11 new papers in 30 daysSee all 47 papers on valsartan

At a glance

The findings reach people, from one lab or study; independent labs found the same change in cells. 10 independent labs in 7 countries; 273 trials, 12 about aging, 128 with no results posted.

“Both fluvastatin and valsartan alone significantly, but to a lesser extent, increased the expression of SIRT1”
Expression of Longevity Genes Induced by a Low-Dose Fluvastatin and Valsartan Combination with the Potential to Prevent/Treat "Aging-Related Disorders"International journal of molecular sciences2019doi:10.3390/ijms20081844

None of its findings points the other way.

Cells: replicated by independent labs. Mice and humans: a single group. Worms or flies: nothing yet.
  • 10 independent labs in 7 countries
  • 273 trials, 12 about aging, 128 with no results posted
  • Funders: Johns Hopkins University and others
  • 1 of 16 findings with company ties
  • 145 of 273 trials sponsored by its developers
  • Human trial3
  • Humans5
  • Animals8
  • Cells4
  • In silico1

Studies in people

1 study gave valsartan to people and measured what changed.

What changedDesignPeopleSource

down: Decreases immune activation-related transcripts in low-density neutrophils

Trialone monthNewly diagnosed hypertensionEuropean journal of pharmacology, Jan 31, 2026

What did studies of valsartan find?

15

Studies of valsartan measured 15 outcomes, among them cellular senescence, wound healing and gout.

Cellular senescence

downin human cells1downin mouse cells1

2 studies
  1. Valsartan decreases cellular senescence in combined lower-dose Ang II and Aβ treatment.

    Cellsin combined lower-dose Ang II and Aβ treatmentbrain vascular smooth muscle cellmales

  2. Valsartan decreases cellular senescence in Ang II-treated cells, co-treated with valsartan.

    Cellsin Ang II-treated cells, co-treated with valsartan

More on Cellular senescence

Wound healing

upin mice1upin pigs1

1 study
  1. Valsartan improves wound healing in pigs (older diabetic pigs).

    Animalsolder diabetic pigs1% topical gelskin1%

  2. Valsartan improves wound healing in mice (diabetic and aged mice).

    Animalsdiabetic and aged mice1% topical gelskin1%

Gout

no changein humans1HR 1.015

1 study
  1. Valsartan was not clearly linked with gout in humans (Newly diagnosed hypertension; combined with amlodipine; compared with non-persistent users) (HR 1.015, 95% CI 0.985–1.045).

    HumansNewly diagnosed hypertension; combined with amlodipine; compared with non-persistent users5 years

More on Gout

LDL cholesterol

downin silico1

1 study
  1. Valsartan decreases LDL cholesterol in silico (β = -2.34 × 10 -3).

    In silico

More on LDL cholesterol

Hypertension

downin mice1

1 study
  1. Valsartan decreases hypertension in tacrolimus-treated mice.

    Animalsin tacrolimus-treated mice

More on Hypertension

Microvascular remodeling

downin mice1

1 study
  1. Valsartan decreases microvascular remodeling in tacrolimus-treated mice.

    Animalsin tacrolimus-treated mice

Immune activation-related transcripts in low-density neutrophils

downin humans1

1 study
  1. Valsartan decreases immune activation-related transcripts in low-density neutrophils in humans (newly diagnosed hypertension).

    Human trialnewly diagnosed hypertensionlow-density neutrophil80 mg/dayone month

More on Immune activation-related transcripts in low-density neutrophils

NLRP3

no changein rats1

1 study
  1. Valsartan showed no clear effect on NLRP3 in OVX rats.

    Animalsin OVX ratshippocampus40 mg/kg/dayfemales

More on NLRP3

BDNF

upin rats1

1 study
  1. Valsartan increases BDNF in OVX rats.

    Animalsin OVX ratshippocampus40 mg/kg/dayfemales

More on BDNF

Oxidative stress and ROS signaling

downin rats1

1 study
  1. Valsartan decreases oxidative stress and ROS signaling in OVX rats.

    Animalsin OVX ratshippocampus40 mg/kg/dayfemales

More on Oxidative stress and ROS signaling

SIRT1

upin humans1

1 study
  1. Valsartan increases SIRT1 in humans.

    Human trial20 mg daily30 daysmales

More on SIRT1

All 15

What is valsartan linked with?

2

Studies link valsartan with 2 measures: cough and transient cerebral ischemic attack.

Cough

upin silico1

1 study
  1. Valsartan raises the risk of cough in silico (odds ratio = 1.67).

    In silico

Transient cerebral ischemic attack

downin silico1

1 study
  1. Valsartan lowers the risk of transient cerebral ischemic attack in silico.

    In silico

More on Transient cerebral ischemic attack

Has valsartan been tested in people?

12 of 273 about aging

Yes: 3 trials and 5 observational studies in people have been published, and 252 trials are registered.

Approved

  • FDA Diovan

    Dec 23, 1996Discontinued

  • FDA Diovan

    Jul 18, 2001Heart Failure, Hypertension, Myocardial Infarction, Ventricular Dysfunction, Left, high blood pressure, Post Myocardial Infarction

  • FDA Prexxartan

    Dec 19, 2017Heart Failure, Hypertension, Myocardial Infarction, Ventricular Dysfunction, Left, high blood pressure, Post Myocardial Infarction

Repurposing

40 of 83

Every condition in trials

  • Motor Activity

    Phase 4Completed2 trials

  • Respiratory distress syndrome

    Phase 4Terminated2 trials

  • Hyperlipidemias

    Phase 3Results posted5 trials

  • De novo renal transplantation

    Phase 3Completed1 trial

  • Hypertension with hyperlipidemia

    Phase 3Completed1 trial

  • Overweight subject

    Phase 1Recruiting1 trial

Stopped

  • NCT02787798TerminatedHeart failure

    Today Entresto treatment has marketing authorization and is available for all patients, that is the reason why study was halted prematurely.

  • NCT00200694TerminatedProteinuria

    difficulty in patients's inclusion

  • NCT04335786TerminatedCOVID-19

    Enrollment was stopped to facilitate successful enrollment for the ACE2RAS-domain of the REMAP-CAP trial.

  • NCT00343499TerminatedAtrial fibrillation

    Inability to recruit

  • NCT01805804TerminatedVentricular remodeling

    Recall of some valsartan preparations. 88 patients enrolled and completed the observation. All patients are in continuous observation and are well.

  • NCT04606563TerminatedAcute kidney injury

    DSMC recommendation due to futility

Who is developing valsartan?

3 companies: Novartis Pharmaceuticals, Shandong New Time Pharmaceutical and Novartis.

Companies
  • Novartis PharmaceuticalsPhase 4Chagas disease, heart failure
  • Shandong New Time PharmaceuticalPhase 3essential hypertension
  • NovartisPhase 3hypertension

Trial sponsors

Latest

Dec 2025: 0Jan 2026: 2Feb 2026: 1Mar 2026: 4Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 1Sep 2026: 2Oct 2026: 9Nov 2026: 221 papers in 12 months

See all 47 papers on valsartan